BioSante finds positive results

LINCOLNSHIRE - BioSante Pharmaceuticals Inc. Thursday announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia patients taking the drug Gleevec. All patients enrolled in the trial used Gleevec for at least one year and still had cancer cells present. The study was conducted by researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland. The research was funded by the National Institutes of Health.